Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype
about
Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.High levels of sarcospan are well tolerated and act as a sarcolemmal stabilizer to address skeletal muscle and pulmonary dysfunction in DMD.Selective Expression of Osteopontin in ALS-resistant Motor Neurons is a Critical Determinant of Late Phase Neurodegeneration Mediated by Matrix Metalloproteinase-9.Regulatory T cells and skeletal muscle regeneration.Outside in: The matrix as a modifier of muscular dystrophy.Macrophages' Role in Tissue Disease and Regeneration.Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1.Genetic modifiers of muscular dystrophy act on sarcolemmal resealing and recovery from injury.Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells.Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells.CCR2 deficiency does not provide sustained improvement of muscular dystrophy in mdx5cv mice.Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.Treating pediatric neuromuscular disorders: The future is now.At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
P2860
Q30841381-5E453880-BAE4-48D1-9FC5-9F27B16331B2Q33640974-68D14351-94F6-489A-84BF-8AB324324737Q36970239-245AB3DE-F536-40CE-8533-61CCBE571254Q38915073-FF84B7DA-7BBD-4160-AF4F-A63D5FD0D67CQ39052032-F83CB0E2-C42C-4376-8DFF-6624F8B01F53Q39271630-F1B2802F-11CC-49DD-B29F-08899A2E3922Q40284169-A1152DD6-DD0F-4F4E-8113-2F4EFDF40371Q44907195-C1F7FA17-332B-4E79-B84F-D55C1811553BQ47153959-ABFB66BE-6582-4FB1-A982-DE0CF7A3388AQ47337769-A08916DC-4BC9-4D37-B0E3-8255A26EC61CQ50953438-32D3B46C-CF19-496E-8B24-FCF279CE7EF4Q51452133-58DF9E87-D49F-405F-97C5-5BE955C97D28Q52648781-1497BB39-3141-4E9B-892A-00ADCE504518Q52756417-28BC2D0C-038C-42DA-903A-0B5036E439DFQ55361250-BF2DFF39-6868-45B0-87DB-4E08CFC93129Q58112184-F8754067-280C-4713-A0A5-B3EE98E8B778
P2860
Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Osteopontin ablation ameliorat ...... o a pro-regenerative phenotype
@en
Osteopontin ablation ameliorat ...... a pro-regenerative phenotype.
@nl
type
label
Osteopontin ablation ameliorat ...... o a pro-regenerative phenotype
@en
Osteopontin ablation ameliorat ...... a pro-regenerative phenotype.
@nl
prefLabel
Osteopontin ablation ameliorat ...... o a pro-regenerative phenotype
@en
Osteopontin ablation ameliorat ...... a pro-regenerative phenotype.
@nl
P2093
P2860
P356
P1476
Osteopontin ablation ameliorat ...... o a pro-regenerative phenotype
@en
P2093
Elisabeth R Barton
H Lee Sweeney
Irina Kramerova
Joana Capote
Leonel Martinez
M Carrie Miceli
Melissa J Spencer
Sylvia Vetrone
P2860
P304
P356
10.1083/JCB.201510086
P407
P577
2016-04-18T00:00:00Z